Introduction
============

Esophageal cancer is a notable global health problem, although its incidence varies throughout the world ([@b1-ol-0-0-7416]--[@b6-ol-0-0-7416]). According to histological classification, esophageal cancer is categorized into esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), each of which possesses different risk factors and pathogenesis ([@b6-ol-0-0-7416]). ESCC frequently occurs in China and other Asian countries, as well as in certain parts of Iran and South Africa, whereas the incidence of EAC is markedly increased in Western countries, including the USA and a number of European countries ([@b6-ol-0-0-7416]). EAC accounts for \~66% of esophageal cancer cases in the USA, whereas ESCC currently accounts for 90% of worldwide esophageal cancer cases ([@b6-ol-0-0-7416]). Thus far, the majority of esophageal cancer cases are diagnosed at advanced stages of the disease, which makes curative surgery unfeasible, leading to a poor overall prognosis in patients with esophageal cancer. Thus, novel strategies and biomarkers are necessary in order to provide early detection, prevention or prediction of treatment responses and the prognosis of esophageal cancer.

In all nucleated cells mitochondria are powerhouses, converting oxygen and glucose into adenosine triphosphate (ATP) through oxidative phosphorylation ([@b7-ol-0-0-7416]). The mitochondrion possesses its own mitochondrial DNA (mtDNA), which is ring-like and double-stranded. Human mtDNA contains non-coding and coding regions, and comprises \~16,569 base pairs ([@b7-ol-0-0-7416]). The 13 polypeptides encoded by the coding region constitute respiratory enzyme complexes, two ribosomal RNAs and a set of 22 transfer RNAs, all of which are necessary for the synthesis of certain mitochondrial peptides ([@b8-ol-0-0-7416]). The displacement loop (D-loop) is a non-coding region serving a function in mtDNA replication and transcription. Thus, D-loop mutations may lead to alterations in mtDNA content or gene expression ([@b9-ol-0-0-7416],[@b10-ol-0-0-7416]). Cells typically contain high levels of mtDNA, and the majority of the copies are determinated at birth ([@b11-ol-0-0-7416]).

Compared with nuclear DNA, the mitochondrial genome is more susceptible to mutation and is sensitive to oxidative damage ([@b8-ol-0-0-7416],[@b12-ol-0-0-7416]). Thus, mitochondrial dysfunction is hypothesized to have a marked influence on tumorigenesis and progression. The copy number of mtDNA is increased during progression of ESCC, glioma, lung and laryngeal cancer, whereas the copy number of mtDNA is decreased in bladder, breast and gastric cancer, and hepatocellular carcinomas, compared with non-cancerous tissues ([@b8-ol-0-0-7416],[@b12-ol-0-0-7416]--[@b16-ol-0-0-7416]). Furthermore, accumulated evidence has demonstrated that in peripheral blood lymphocytes, altered mtDNA content is closely associated with the risk of certain types of cancer ([@b17-ol-0-0-7416]--[@b24-ol-0-0-7416]). However, the association between various copy numbers of mtDNA and prognosis in ESCC remains unresolved. In the present study, altered mtDNA content in normal esophageal tissues and ESCC tissues was investigated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and the associations between mtDNA content and clinicopathological features, and the prognosis of patients with ESCC were also explored.

Materials and methods
=====================

### Patients and tissue samples

Approval for the present study was obtained from Human Ethics Committee and Institutional Review Board, Xi\'an Jiaotong University (Xi\'an, China). A total of 141 paraffin-embedded ESCC tissue samples were collected from the First Affiliated Hospital of Xi\'an Jiaotong University (Xi\'an, China) between January 2002 and September 2010. Additionally, 45 samples were obtained from esophagitis patients that underwent endoscopy for biopsy, and were used as control subjects. Patients with chemoradiotherapy were excluded. Written informed consent was obtained from each patient prior to surgery. The diagnosis of esophageal diseases was based on histological examination according to the World Health Organization diagnosis standard of esophageal diseases ([@b25-ol-0-0-7416]). The clinicopathological data of the patients was collected from their medical records and the results are presented in [Table I](#tI-ol-0-0-7416){ref-type="table"}.

### DNA preparation

Serial sections were cut at 5 µm from paraffin embedded tumor and control tissues. One section from each sample was stained by hematoxylin and eosin (H&E) staining as described below. Briefly after deparaffinizing and hydrating the tissue sections, slides were incubated with hematoxylin solution in a staining jar for 10 min to stain the nuclei. Then the slides were transferred to a staining jar with running water until the water ran clear. Slides were then transferred to a staining jar with Eosin solution for 3 min. Successively transfer the slides into staining jars with 70% ethanol for 20 sec, 90% ethanol for 20 sec, 100% ethanol for 1 min and xylene for 3 min. Slides were mounted with xylene-based mounting media and covered with cover slides. The representative tumor tissue was examined by an expert surgical pathologist at The Department of Pathology of the First Affiliated Hospital of Xi\'an Jiaotong University (Xi\'an, China) for esophageal cancer. The tumor tissues were isolated through manual microdissection using an inverted microscope according to the H&E marker. DNA was then isolated from the tumor tissues as described previously ([@b26-ol-0-0-7416]). Briefly, after a treatment for 12 h at room temperature with xylene to remove paraffin, the tissues were then subjected to digestion with 1% sodium dodecyl sulfate (SDS) and proteinase K at 48°C for 48 h, with addition of several spiking aliquots of concentrated proteinase K to facilitate digestion. DNA was subsequently isolated using a standard phenol-chloroform extraction and ethanol precipitation protocol, and kept at −80°C until use.

### mtDNA content analysis

The relative mtDNA content of the patients with ESCC and the control subjects was measured using RT-qPCR as described previously ([@b15-ol-0-0-7416]). The specific primers and TaqMan probes for *MT-ND1* (mitochondrially encoded NADH dehydrogenase 1) and the β-actin gene were designed using Primer Express software (version 3.0; Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA) ([Table II](#tII-ol-0-0-7416){ref-type="table"}). Each sample was prepared in triplicate. To standardize the input DNA, β-actin was measured in parallel as a reference gene. Normal leukocyte DNA was used in serial dilutions to establish standard curves. The relative mtDNA content of each sample was measured as described previously ([@b18-ol-0-0-7416]).

### Statistical analysis

The copy number of mtDNA between patients with ESCC and control subjects was compared using a Mann-Whitney *U* test. The association of mtDNA content with clinicopathological features was assessed using univariate analysis. Multivariate models were developed and adjusted according to age, tumor size, differentiation and lymph node metastasis. Survival time was determined from the day of primary tumor resection to the day of cancer-associated mortality or last clinical follow-up. The Kaplan-Meier estimator method was used to analyze patient survival stratified by mtDNA content variations and the difference between the Kaplan-Meier curves was assessed using a log-rank test. A multivariate Cox\'s proportional hazards regression model was applied to calculate the hazard ratio (HR) with 95% confidence intervals (CIs) for prognosis evaluation. A multivariate Cox\'s regression analysis was performed to assess the influence of mtDNA content on patient prognosis, which was independent of the number of lymph node metastases, tumor invasion and differentiation. Statistical analyses were performed using SPSS software (version 11.5; SPSS, Inc., Chicago, IL, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Relative mtDNA content in ESCC

RT-qPCR was performed to analyze the mtDNA copy number in 141 patients with ESCC and 45 control subjects. As presented in [Fig. 1](#f1-ol-0-0-7416){ref-type="fig"}, the relative mean mtDNA content was significantly increased in patients with ESCC (4.67±3.88 copies) compared with that in control subjects (2.24±1.80 copies) (P\<0.001). The median values among patients with ESCC and control subjects were 3.15 copies (interquartile range between 0.53 and 18.28 copies) and 1.80 copies (interquartile range between 0.47 and 7.50 copies), respectively, suggesting that the majority of patients with ESCC had increased mtDNA content compared with control subjects, which was consistent with a previous study ([@b5-ol-0-0-7416]). The possible difference in mtDNA content in tumor tissues with regard to selected clinicopathological features was also evlaluated. As presented in [Fig. 2](#f2-ol-0-0-7416){ref-type="fig"}, no significant differences were identified in mtDNA copy number with reagrd to sex, age, tumor localization, tumor size, differentiation, tumor invasion, Tumor-Node-Metastasis stage ([@b27-ol-0-0-7416]) and lymph node metastasis. The group of patients who sucumbed to the disease exhibited an increased mtDNA copy number compared with the group of patients who did not succumb. Although no statistically significant difference was observed, there was a notable trend toward a positive association between mtDNA copy number and survival status of patients with ESCC (P=0.054).

### Association between altered mtDNA content and clinicopathological features of ESCC

To investigate the association between mtDNA copy number and the clinicopathological features of ESCC, the median mtDNA copy number (3.14 copies) in the ESCC samples was selected as a threshold value. Using this threshold value, the ESCC samples were classified into two groups, namely increased mtDNA content (≥3.14 copies) and decreased mtDNA content (\<3.14 copies). As presented in [Table III](#tIII-ol-0-0-7416){ref-type="table"}, mtDNA copy number variations was significantly associated with survival status in patients with ESCC. Compared with the control, the patients with ESCC exhibiting increased mtDNA content had an increased mortality rate \[odds ratio (OR), 1.95; 95% confidence interval (CI), 1.04--3.64; P=0.04\]. Multivariable logistic regression was performed to evaluate the independent association of variable mtDNA copy number with age, tumor size, differentiation and lymph node metastasis. As presented in [Table IV](#tIV-ol-0-0-7416){ref-type="table"} the patients with increased mtDNA copy number had a 2.41 times higher risk of mortality than those with decreased mtDNA copy number. The data identified that increased mtDNA copy number remained positively associated with survival status following adjustment (OR, 2.41; 95% CI, 1.13--5.13; P=0.02).

### Effect of increased mtDNA content on prognosis of ESCC

The Kaplan-Meier estimator survival curves and log-rank test were used to assess the effect of altered mtDNA content on the survival time of patients with ESCC. As presented in [Fig. 3](#f3-ol-0-0-7416){ref-type="fig"}, the patients with increased mtDNA copy number experienced shorter survival times than those with decreased mtDNA copy number (median survival time: 42.00 vs. 38.00 months; P=0.03). Similarly, Cox\'s unvariate regression analysis demonstrated a marked association of increased mtDNA copy number with poor patient survival \[hazard ratio (HR), 1.76; 95% CI, 1.06--2.97, P=0.03; [Table V](#tV-ol-0-0-7416){ref-type="table"}\] as well as age \[HR, 1.75; 95% CI, 1.05--2.91, P=0.03\] and TNM stage \[HR, 2.40; 95% CI, 1.44--3.99, P\<0.01; [Table V](#tV-ol-0-0-7416){ref-type="table"}\]. Additionally, Cox\'s multivariate regression analysis indicated that increased mtDNA content is a predictor of increased mortality for patients with ESCC (HR, 1.91; 95% CI, 1.13--3.22; P=0.02), and is an independent variable with regard to the age and tumor stage ([Table V](#tV-ol-0-0-7416){ref-type="table"}).

Discussion
==========

The primary function of the mitochondria is to produce the energy source ATP. Additionally, the mitochondria also serve functions in numerous cell processes, including cell differentiation, growth, death, cell cycle regulation and signal transduction ([@b28-ol-0-0-7416]). A previous study identified that extranuclear DNA, including mtDNA, and intranuclear genetic materials may have an effect on ESCC and the development of other tumors ([@b8-ol-0-0-7416]). It was identified that mtDNA content was significantly increased in patients with ESCC compared with control subjects, as supported by the results of a previous study ([@b5-ol-0-0-7416]). These data suggest that increased mtDNA content may be associated with esophageal tumorigenesis and the high mortality rate of patients with ESCC.

Changes in the mtDNA or mitochondrial dysfunction are frequently observed in tumor cells ([@b8-ol-0-0-7416],[@b12-ol-0-0-7416]--[@b16-ol-0-0-7416]). Several prior studies indicated that mtDNA content is increased in different types of cancer, including ESCC ([@b5-ol-0-0-7416],[@b8-ol-0-0-7416],[@b14-ol-0-0-7416]--[@b16-ol-0-0-7416]). This proliferation of mtDNA is possibly a compensation mechanism induced by an energy shortage in tumor cells ([@b29-ol-0-0-7416],[@b30-ol-0-0-7416]). This is supported by a previous study, which demonstrated that relative mtDNA copy number increased progressively in normal esophageal mucosa, ESCC and metastatic lymph nodes, and that increased mtDNA content contributed to the increased bioenergetic capbility of the mitochondria, further promoting tumor invasion of ESCC ([@b5-ol-0-0-7416]).

In addition to its function supplying energy, increased mtDNA content may be associated with mtDNA escape in cancer. It has been identified that mtDNA escape is an essential exchange between the nuclear and mitochondrial genomes in yeast cells ([@b31-ol-0-0-7416],[@b32-ol-0-0-7416]). Similar to yeast, mammalian cells may require increased mtDNA content for the communication of genetic material between mitochondrial and nuclear genomes ([@b33-ol-0-0-7416],[@b34-ol-0-0-7416]). In line with this, a previous study utilizing fluorescence *in situ* hybridization demonstrated that mitochondrial sequence hybridization is observed in the nuclei more frequently in glioma tissues compared with normal brain tissues ([@b33-ol-0-0-7416]). Furthermore, it has been demonstrated that mtDNA sequences are able to interrupt intronic regions of certain cancer-associated genes, including the tumor suppressor gene mothers against decapentaplegic homolog 2 ([@b35-ol-0-0-7416]). mtDNA is able to cross with the nuclear genome in intronic and exonic regions ([@b36-ol-0-0-7416],[@b37-ol-0-0-7416]). Thus, increased mtDNA content may be symptomatic of an early genetic event contributing to tumorigenesis by supplying the energy for tumor cell growth and interrupting the function of specific tumor suppressor genes.

Since increased mtDNA content may contribute to tumorigenesis, a number of studies have been performed in order to explore the association between altered mtDNA content and clinical outcomes of patients with cancer ([@b38-ol-0-0-7416],[@b39-ol-0-0-7416]). In the present study, it was revealed that increased mtDNA content was associated with the survival status of patients with ESCC, and that the patients with high mtDNA content experienced significantly shorter survival times than those with low mtDNA content. When multivariate survival analysis was performed using Cox\'s regression model, it was once again identified that increased mtDNA content was associated with poorer patient survival rates. Taken together, these findings suggest that an altered mtDNA copy number may be a prognostic signature in ESCC.

A number of novel systems for copy number variation analysis have been developed, including magnetic nanoparticles-chemiluminescence detection (a combination of magnetic separation and chemiluminescence) ([@b40-ol-0-0-7416]), which has been used to analyze the copy numbers of porcine endogenous retroviruses and proviruses from Chinese Bama minipigs. This system possessess the advantages of being low-cost, simple, and providing high specificity and sensitivity compared with RT-qPCR, and as a result it, may be used in future studies ([@b41-ol-0-0-7416]).

In summary, the mtDNA content in patients with ESCC was investigated and it was demonstrated that increased mtDNA content may have an important impact on the tumorigenic phenotype of ESCC. The results of the present study also revealed that increased mtDNA copy number is an independent prognostic factor in ESCC, which may serve as a biomarker for predicting poor prognosis in patients with ESCC.
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![mtDNA copy number of each individual case of esophageal cancer and normal esophageal tissue. Reverse transcription-quantitative polymerase chain reaction was performed to analyze mtDNA copy number in patients with esophageal squamous cell carcinoma and normal esophageal tissues (control subjects). Horizontal lines represent mean ± standard error of the mean. T, tumor tissues; N, control subjects; mtDNA, mitochondrial DNA.](ol-15-01-1014-g00){#f1-ol-0-0-7416}

![Association of mtDNA copy number with clinicopathological characteristics in ESCC. The copy number of mtDNA was analyzed using reverse transcription-quantitative polymerase chain reaction. Circles represent the mtDNA copy number of each case. Horizontal lines represent mean ± standard error of the mean. Sample means were compared using the Mann-Whitney U test. mtDNA, mitochondrial DNA; ESCC, esophageal squamous cell carcinoma; FM, female; M, male; well, well/moderate differentiation; poor, poor/undifferentiated; ES, early-stage; LS, late-stage; S, smoking; NS, non-smoking; N, no metastasis present; Y, yes metastasis present; TNM, Tumor-Node-Metastasis.](ol-15-01-1014-g01){#f2-ol-0-0-7416}

![Kaplan-Meier estimator curves stratified by mtDNA copy number. Kaplan-Meier estimator survival analysis was performed according to copy number variations of mtDNA in this cohort of patients with ESCC. The data identified that increased mtDNA copy number (≥3.14 copies) was markedly associated with decreased overall survival time of patients with ESCC. mtDNA, mitochondrial DNA; ESCC, esophageal squamous cell carcinoma.](ol-15-01-1014-g02){#f3-ol-0-0-7416}

###### 

Clinicopathological characteristics of patients with ESCC.

  Characteristics                Value
  ------------------------------ ------------
  Gender, n (%)                  
    Male                         111 (78.7)
    Female                       30 (21.3)
  Age, years                     
    Mean                         58.3
    SD                           8.5
  Tumor localization, n (%)      
    Upper esophagus              32 (22.7)
    Middle esophagus             75 (53.2)
    Lower esophagus              34 (24.1)
  Tumor size, n (%)              
    \<3 cm^3^                    36 (25.5)
    3-5 cm^3^                    72 (51.1)
    \>5 cm^3^                    33 (23.4)
  Differentiation, n (%)         
    Well/moderate                112 (79.4)
    Poor/undifferentiated        29 (20.6)
  Tumor invasion, n (%)          
    T1                           15 (10.6)
    T2                           26 (18.4)
    T3                           72 (51.1)
    T4                           28 (19.9)
  TNM stage, n (%)               
    I                            15 (10.6)
    II                           73 (51.8)
    III                          50 (35.5)
    IV                           3 (2.1)
  Lymph node metastasis, n (%)   
    Yes                          58 (41.1)
    No                           83 (58.9)
  No. of LNM, n (%)              
    N0                           83 (58.9)
    N1 (1--6)                    51 (36.2)
    N2 (7--15)                   7 (4.9)
    N3 (≥16)                     0 (0.0)
  Survival status, n (%)         
    Deceased                     61 (43.3)
    Alive                        80 (56.7)

mtDNA, mitochondrial DNA; ESCC, esophageal squamous cell carcinoma; SD, standard deviation; TNM, Tumor-Node-Metastasis; LNM, lymph, node and metastasis.

###### 

Primer and TaqMan probe sequences used in this study.

  Genes      Forward primer sequence (5′-3′)        Probe sequence (5′-3′)   Reverse primer sequence (5′-3′)
  ---------- -------------------------------------- ------------------------ ------------------------------------------
  *MT-ND1*   CCCCTAAAACCCGCCACATCCGCCCCGACC-TAMRA   6FAM-ACCCTCTACATCA       GTAGAAGAGCGATGGTGAGAGC
  β-actin    TCACCCACACTGTGCCCATCTACGA              6FAM-ATGCCCTCCC          TCGGTGAGGATCTTCATGAGGTACCATGCCATCC-TAMRA

MT-ND1, mitochondrially encoded NADH dehydrogenase 1; FAM, 6-carboxyfluorescein; TAMRA, tetramethylrhodamine.

###### 

Copy number variations of mitochondrial DNA in esophageal squamous cell carcinoma: Univariate associations with clinicopathological characteristics.

  Characteristics                                                   Odds ratio (95% CI)   P-value
  ----------------------------------------------------------------- --------------------- ---------
  Sex                                                               0.98 (0.44--2.20)     0.97
  Age, years^[a](#tfn3-ol-0-0-7416){ref-type="table-fn"}^           1.37 (0.71--2.66)     0.35
  Tumor localization^[b](#tfn4-ol-0-0-7416){ref-type="table-fn"}^   0.90 (0.57--1.41)     0.64
  Tumor size, cm^3[c](#tfn5-ol-0-0-7416){ref-type="table-fn"}^      1.87 (0.83--4.20)     0.13
  Differentiation^[d](#tfn6-ol-0-0-7416){ref-type="table-fn"}^      1.33 (0.76--2.33)     0.33
  Tumor invasion^[e](#tfn7-ol-0-0-7416){ref-type="table-fn"}^       1.31 (0.48--3.55)     0.59
  TNM stage^[f](#tfn8-ol-0-0-7416){ref-type="table-fn"}^            0.78 (0.30--2.01)     0.61
  Lymph node metastasis                                             0.74 (0.38--1.46)     0.39
  Survival status^[g](#tfn9-ol-0-0-7416){ref-type="table-fn"}^      1.95 (1.04--3.64)     0.04

Age (per 10 years)

Tumor localization (upper esophagus; middle esophagus; lower esophagus)

Tumor size (≤3 cm^3^; \>3 and ≤5 cm^3^; \>5 cm^3^)

Differentiation (well or moderate; poor or undifferentiated)

Tumor invasion (T1; T2; T3; T4)

TNM stage (I; II; III; IV)

Survival status (alive; deceased). CI, confidence interval; TNM, Tumor-Node-Metastasis.

###### 

Copy number variations of mitochondrial DNA in esophageal squamous cell carcinoma: Multivariable associations with clinicopathological characteristics.

  Characteristics                                                 Odds Ratio (95% CI)   P-value
  --------------------------------------------------------------- --------------------- ---------
  Sex                                                             1.07 (0.43--2.64)     0.89
  Age^[a](#tfn10-ol-0-0-7416){ref-type="table-fn"}^               1.01 (0.97--1.06)     0.55
  Tumor size^[b](#tfn11-ol-0-0-7416){ref-type="table-fn"}^        1.58 (0.90--2.77)     0.11
  Differentiation^[c](#tfn12-ol-0-0-7416){ref-type="table-fn"}^   1.72 (0.90--2.77)     0.99
  Tumor invasion^[d](#tfn13-ol-0-0-7416){ref-type="table-fn"}^    0.67 (0.16--2.81)     0.58
  TNM stage^[e](#tfn14-ol-0-0-7416){ref-type="table-fn"}^         0.69 (0.23--2.02)     0.50
  Lymph node metastasis                                           0.68 (0.16--2.86)     0.59
  Survival status^[f](#tfn15-ol-0-0-7416){ref-type="table-fn"}^   2.41 (1.13--5.13)     0.02
  Smoking^[g](#tfn16-ol-0-0-7416){ref-type="table-fn"}^           1.15 (0.47--2.79)     0.75

Age (per 10 years)

Tumor size (≤3 cm^3^; \>3 and ≤5 cm^3^; \>5 cm^3^)

Differentiation (well or moderate; poor or undifferentiated)

Tumor invasion (T1; T2; T3; T4)

TNM stage (I; II; III; IV)

Survival status (alive; deceased)

Smoking (smoking; no smoking). CI, confidence interval; TNM, Tumor-Node-Metastasis.

###### 

Prognostic value of clinicopathological factors and copy number variation of mitochondrial DNA in univariate and multivariate Cox\'s regression analysis (n =141).

                                                                 Univariate analysis   Multivariate analysis                       
  -------------------------------------------------------------- --------------------- ----------------------- ------------------- --------
  Copy number                                                                            0.03                                        0.02
    \<3.14                                                       1.00                                          1.00                
    ≥3.14                                                        1.76 (1.06--2.97)                             1.91 (1.13--3.22)   
  Age, years^[a](#tfn17-ol-0-0-7416){ref-type="table-fn"}^                               0.03                                        0.02
    \<60                                                         1.00                                          1.00                
    ≥60                                                          1.75 (1.05--2.91)                             1.89 (1.13--3.17)   
  Tumor invasion^[b](#tfn18-ol-0-0-7416){ref-type="table-fn"}^                           0.06                                        0.18
    T1/T2                                                        1.00                                          1.00                
    T3/T4                                                        2.65 (0.96--7.30)                             2.03 (0.72--5.68)   
  TNM stage^[c](#tfn19-ol-0-0-7416){ref-type="table-fn"}^                              \<0.01                                      \<0.01
    I/II                                                         1.00                                          1.00                
    III/IV                                                       2.40 (1.44--3.99)                             2.54 (1.50--4.30)   

Age (per 10 years)

Tumor invasion (T1/T2; T3/T4)

TNM stage (I/II; III/IV). CI, confidence interval; TNM, Tumor-Node-Metastasis.
